University of Kansas

University of Michigan

Hylapharm, LLC

Ti Zhang

Laird Forrest

Daniel J Aires

Shuang Cai

Qiuhong Yang

Mark S Cohen

Jordan Hunt

Steven R Buchman

Alexis Donneys

Noah Nelson

Ryan Moulder

Ruolin Lu

Peter Kleindl

Chad E Groer

Chad Groer

Marcus Laird Forrest

Shaofeng Duan

The present invention relates to novel therapeutic nanoparticles. In particular, the present invention is directed to nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) with angiogenesis-activating-agents, methods of synthesizing the same, devices or compositions comprising such nanoparticles, as well as systems and methods utilizing the nanoparticles (e.g., in therapeutic settings for enhancing and/or activating angiogenesis at targeted tissue region).

Devices, compositions and related methods for accelerating and enhancing bone repair

The present technology is directed to TLR7 and TLR8 agonist compounds, compositions, and methods of using the same for the treatment of cancers and as vaccine adjuvants.

Imidazoquinoline compounds and prodrugs thereof

Provided are platinum(IV) compounds of Formula I or pharmaceutically acceptable salts thereof. Also provided are compositions including such compounds as well as methods of using the same.

Platinum(IV) conjugates and methods of use

A multi-arm, star-shaped polymer composition can be configured for drug delivery and imaging applications in vivo. The star polymer architecture can be synthesized using living radical polymerization techniques, including reversible addition-fragmentation chain transfer and macromolecular design via the interchange of xanthates with a broad range of reaction conditions and functional groups. The star-shaped polymeric carriers can be tailored for preferential delivery of chemotherapeutics into the tumor-draining lymphatics via subcutaneous, peritumoral or intratumoral injections. The carriers can be loaded with the chemotherapeutic agents from about 10% to about 25% w/w. In addition, the carriers can be loaded with imaging agents from about 5% to about 10% w/w. The molecular weights of the polymeric carriers can be about 40 kDa to about 130 kDa. The chemotherapeutics can be cisplatin, geldanamycin or nitric oxide-donating prodrugs. The imaging agent can be a near-infrared dye, such as IR820.

Drug and imaging agent delivery compositions and methods

Growing community of inventors

Lawrence, KS, United States of America

Ti Zhang